Core Points - Argyle Resources Corp. plans to complete an offering of up to 2,000,000 units at a price of C$0.50 per unit, aiming for gross proceeds of up to C$1,000,000 [1] - Each unit consists of one common share and one-half of a share purchase warrant, with the warrant allowing the purchase of one share at C$0.55 for 24 months [1] - The offering will be conducted under the listed issuer financing exemption, allowing for no resale restrictions in most Canadian provinces [2] Financial Details - The offering is scheduled to close on or about June 6, 2025, and is subject to raising a minimum of C$750,000 [4] - Proceeds from the offering will be used for general working capital purposes [4] Company Overview - Argyle Resources Corp. is a junior mineral exploration company focused on acquiring and evaluating natural resource properties in North America [6] - The company holds a 100% interest in several silica projects in Québec and has options to acquire additional properties in Ontario and Nova Scotia [6] - Established in 2023, the company is headquartered in Calgary, Alberta [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...

Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be present ...

Core Insights - Globe Life Inc. reported a net income of $3.01 per diluted common share for Q1 2025, an increase from $2.67 in the same quarter last year, while net operating income was $3.07 per diluted common share, exceeding management's expectations [1][6][11] Financial Performance - Net operating income increased by 10% year-over-year, from $2.78 to $3.07 per diluted common share [6][7] - Net income as a return on equity (ROE) was 19.0%, down from 21.3% in the previous year [6][11] - Total premium revenue for life insurance rose by 3% to $829.86 million, while health insurance premiums increased by 8% to $369.79 million, leading to a total premium revenue of $1.20 billion, a 5% increase from the previous year [13][43] Insurance Operations - Life insurance accounted for 80% of the insurance underwriting margin, while health insurance made up 20% [12] - Life underwriting margin increased by 9% year-over-year, while health underwriting margin decreased by 10% [15][19] - Net sales of life insurance declined by 1%, whereas net health sales increased by 24% [13][19] Investment Performance - Net investment income decreased by 1% to $280.61 million, while excess investment income fell by 18% to $35.87 million [25][26] - The investment portfolio totaled $20.01 billion, with fixed maturities making up 87% of the total [28][29] Shareholder Actions - The company repurchased 1.5 million shares of common stock at a total cost of $177 million, averaging $121.70 per share [34] - Shareholders' equity, excluding accumulated other comprehensive income (AOCI), was reported at $7.40 billion [11][12] Guidance - Globe Life projects net operating income between $13.45 to $14.05 per diluted common share for the year ending December 31, 2025, reaffirming previous guidance [36]

Group 1 - aTyr Pharma is preparing for its first pivotal event of the year, which is an interim readout, although it is considered the least interesting by some analysts [1] - The company is part of a broader focus on growth markets, particularly in the biotech sector, which is seen as having significant potential [1] - The investment strategy includes looking for undervalued stocks with strong scientific backgrounds, indicating a focus on fundamental analysis [1] Group 2 - The analyst has a beneficial long position in aTyr Pharma's shares, indicating confidence in the company's future performance [2] - The article expresses personal opinions and does not involve compensation from the company, suggesting an independent analysis [2] - There is no business relationship with aTyr Pharma, reinforcing the objectivity of the analysis [2]